<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893879</url>
  </required_header>
  <id_info>
    <org_study_id>BRSNSTU0028</org_study_id>
    <secondary_id>NCI-2012-02290</secondary_id>
    <nct_id>NCT01893879</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in Patients At High Risk After Undergoing Axillary Lymph Node Dissection</brief_title>
  <official_title>Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies ketoprofen in preventing lymphedema in patients at
      high risk after undergoing axillary lymph node dissection. Ketoprofen may prevent lymphedema
      in patients undergoing axillary lymph node dissection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the efficacy of ketoprofen in improving chronic lymphedema while further
      elucidating the role of inflammatory and lymph angiogenic processes in the pathogenesis of
      this disease.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive ketoprofen orally (PO) thrice daily (TID) for up to 1 year in the
      absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive placebo PO TID for up to 1 year in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of lymphedema and/or severity of lymphedema</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lymphedema</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I (ketoprofen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ketoprofen PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoprofen</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (ketoprofen)</arm_group_label>
    <other_name>capisten</other_name>
    <other_name>Orudis</other_name>
    <other_name>Oruvail</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (ketoprofen)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Axillary lymph node dissection within the preceding 12 months

        Exclusion Criteria:

          -  Patients with active cancer

          -  Patients with lymphedema

          -  Infection or bleeding tendency

          -  Patients with medical contraindications to nonsteroidal anti-inflammatory drugs
             (NSAIDs), including history of allergies, know gastrointestinal intolerance

          -  Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive
             heart failure, neurological or psychological impairment) that would impair the
             patients' ability to participate

          -  Persons not competent to consent

          -  Patients on aspirin therapy

          -  Minors (&lt; 18 years of age)

          -  Pregnant and/or lactating women

          -  Males
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Rockson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Hospitals and Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanley Rockson</last_name>
      <phone>650-498-7061</phone>
      <email>srockson@cvmed.stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Stanley Rockson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
